Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

DNA Repair in Prostate Cancer: Biology and Clinical Implications

Open access
Mateo, Joaquin, Boysen, Gunther, Barbieri, Christopher E., Bryant, Helen E., Castro, Elena, Nelson, Pete S., Olmos, David, Pritchard, Colin C., Rubin, Mark A., de Bono, Johann S.·2017·European Urology

Abstract

CONTEXT: For more precise, personalized care in prostate cancer (PC), a new classification based on molecular features relevant for prognostication and treatment stratification is needed. Genomic aberrations in the DNA damage repair pathway are common in PC, particularly in late-stage disease, and may be relevant for treatment stratification. OBJECTIVE: To review current knowledge on the prevalence and clinical significance of aberrations in DNA repair genes in PC, particularly in metastatic disease. EVIDENCE ACQUISITION: A literature search up to July 2016 was conducted, including clinical trials and preclinical basic research studies. Keywords included DNA repair, BRCA, ATM, CRPC, prostate cancer, PARP, platinum, predictive biomarkers, and hereditary cancer. EVIDENCE SYNTHESIS: We review how the DNA repair pathway is relevant to prostate carcinogenesis and progression. Data on how this may be relevant to hereditary cancer and genetic counseling are included, as well as data from clinical trials of PARP inhibitors and platinum therapeutics in PC. CONCLUSIONS: Relevant studies have identified genomic defects in DNA repair in PCs in 20-30% of advanced castration-resistant PC cases, a proportion of which are germline aberrations and heritable. Phase 1/2 clinical trial data, and other supporting clinical data, support the development of PARP inhibitors and DNA-damaging agents in this molecularly defined subgroup of PC following success in other cancer types. These studies may be an opportunity to improve patient care with personalized therapeutic strategies. PATIENT SUMMARY: Key literature on how genomic defects in the DNA damage repair pathway are relevant for prostate cancer biology and clinical management is reviewed. Potential implications for future changes in patient care are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.08.037

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 62

  1. Lorente, 2015, Sequencing of agents in castration-resistant prostate cancer, Lancet Oncol, 16, e279, 10.1016/S1470-2045(15)70033-1 · DOI
  2. Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
  3. Rubin, 2015, Genomic correlates to the newly proposed grading prognostic groups for prostate cancer, Eur Urol, 69, 2
  4. Baca, 2013, Punctuated evolution of prostate cancer genomes, Cell, 153, 666, 10.1016/j.cell.2013.03.021 · DOI · Paper page
  5. Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, 44, 685, 10.1038/ng.2279 · DOI · Paper page
  6. Berger, 2011, The genomic complexity of primary human prostate cancer, Nature, 470, 214, 10.1038/nature09744 · DOI · Paper page
  7. Abeshouse, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 · DOI · Paper page
  8. Meeks, 2016, BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers, J Natl Cancer Inst, 108, 10.1093/jnci/djv315 · DOI
  9. Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur Urol, 63, 920, 10.1016/j.eururo.2012.08.053 · DOI · Paper page
  10. Kumar, 2016, Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer, Nat Med, 22, 369, 10.1038/nm.4053 · DOI · Paper page
  11. Beltran, 2016, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat Med, 22, 298, 10.1038/nm.4045 · DOI · Paper page
  12. Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 · DOI · Paper page
  13. Wood, 2011, Human DNA repair genes, Science, 1284, 241
  14. Saleh-Gohari, 2005, Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks, Mol Cell Biol, 25, 7158, 10.1128/MCB.25.16.7158-7169.2005 · DOI · Paper page
  15. Goodwin, 2013, A hormone-DNA repair circuit governs the response to genotoxic insult, Cancer Discov, 3, 1254, 10.1158/2159-8290.CD-13-0108 · DOI · Paper page
  16. Polkinghorn, 2013, Androgen receptor signaling regulates DNA repair in prostate cancers, Cancer Discov, 3, 1245, 10.1158/2159-8290.CD-13-0172 · DOI · Paper page
  17. Ju, 2006, A topoisomerase IIβ-mediated dsDNA break required for regulated transcription, Science, 312, 1798, 10.1126/science.1127196 · DOI · Paper page
  18. Mani, 2010, Induced chromosomal proximity and the genesis of gene fusions in prostate cancer, Science, 326, 2009
  19. Boysen, 2015, SPOP mutation leads to genomic instability in prostate cancer, Elife, 4, e09207, 10.7554/eLife.09207 · DOI · Paper page
  20. Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat Commun, 5, 4988, 10.1038/ncomms5988 · DOI · Paper page
  21. Chen, 2001, Defects of DNA mismatch repair in human prostate cancer, Cancer Res, 61, 4112
  22. Decker, 2016, Biallelic BRCA2 mutations shape the somatic mutational landscape of aggressive prostate tumors, Am J Hum Genet, 98, 1, 10.1016/j.ajhg.2016.03.003 · DOI
  23. Castro, 2015, High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers, Ann Oncol, 26, 2293, 10.1093/annonc/mdv356 · DOI
  24. Carter, 1992, Mendelian inheritance of familial prostate cancer, Proc Natl Acad Sci U S A, 89, 3367, 10.1073/pnas.89.8.3367 · DOI · Paper page
  25. Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 · DOI · Paper page
  26. Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146 · DOI · Paper page
  27. Eeles, 2014, The genetic epidemiology of prostate cancer and its clinical implications, Nat Rev Urol, 11, 18, 10.1038/nrurol.2013.266 · DOI · Paper page
  28. Bancroft, 2014, Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study, Eur Urol, 66, 489, 10.1016/j.eururo.2014.01.003 · DOI · Paper page
  29. Haraldsdottir, 2014, Prostate cancer incidence in males with Lynch syndrome, Genet Med, 16, 553, 10.1038/gim.2013.193 · DOI
  30. Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 · DOI · Paper page
  31. Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 · DOI · Paper page
  32. Gallagher, 2012, Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer, BJU Int, 109, 713, 10.1111/j.1464-410X.2011.10292.x · doi:10.1111/j.1464-410x.2011.10292.x
  33. Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871 · DOI · Paper page
  34. Dobzhansky, 1946, Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura, Genetics, 31, 269, 10.1093/genetics/31.3.269 · DOI · Paper page
  35. McCabe, 2006, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition, Cancer Res, 66, 8109, 10.1158/0008-5472.CAN-06-0140 · DOI · Paper page
  36. Murai, 2014, Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib, Mol Cancer Ther, 13, 433, 10.1158/1535-7163.MCT-13-0803 · DOI · Paper page
  37. Patel, 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells, Proc Natl Acad Sci U S A, 108, 3406, 10.1073/pnas.1013715108 · DOI · Paper page
  38. Bryant, 2009, PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination, EMBO J, 28, 2601, 10.1038/emboj.2009.206 · DOI · Paper page
  39. Murai, 2012, Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res., 72, 5588, 10.1158/0008-5472.CAN-12-2753 · DOI · Paper page
  40. Schiewer, 2012, Dual roles of PARP-1 promote cancer growth and progression, Cancer Discov, 2, 1134, 10.1158/2159-8290.CD-12-0120 · DOI · Paper page
  41. Brenner, 2011, Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer, Cancer Cell, 19, 664, 10.1016/j.ccr.2011.04.010 · DOI · Paper page
  42. Kumar, 2010, Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair, Proc Natl Acad Sci U S A, 107, 7491, 10.1073/pnas.0914242107 · DOI · Paper page
  43. McCabe, 2015, Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM, Cancer Res, 75, 2159, 10.1158/0008-5472.CAN-14-3502 · DOI
  44. Hussain, 2016, Co-targeting androgen receptor (AR) and DNA repair: a randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/− the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012), J Clin Oncol, 34, 5010, 10.1200/JCO.2016.34.15_suppl.5010 · doi:10.1200/jco.2016.34.15_suppl.5010
  45. Sandhu, 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial, Lancet Oncol, 2045, 1
  46. Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 · DOI · Paper page
  47. Tutt, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, Lancet, 376, 235, 10.1016/S0140-6736(10)60892-6 · DOI · Paper page
  48. Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 · DOI · Paper page
  49. Audeh, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial, Lancet, 376, 245, 10.1016/S0140-6736(10)60893-8 · DOI · Paper page
  50. Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
  51. Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 · DOI · Paper page
  52. Shen, 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency, Clin Cancer Res., 19, 5003, 10.1158/1078-0432.CCR-13-1391 · DOI · Paper page
  53. de Bono, 2013, First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors, J Clin Oncol, 31, 2580, 10.1200/jco.2013.31.15_suppl.2580 · DOI
  54. Ihnen, 2013, Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer, Mol Cancer Ther, 12, 1002, 10.1158/1535-7163.MCT-12-0813 · DOI
  55. Hussain, 2014, Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer, Invest New Drugs, 32, 904, 10.1007/s10637-014-0099-0 · DOI
  56. Mateo, 2016, An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib, Target Oncol, 11, 401, 10.1007/s11523-016-0435-8 · DOI
  57. Chao, 2014, Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP, Mol Cancer Res, 12, 1755, 10.1158/1541-7786.MCR-14-0173 · DOI
  58. Sternberg, 2009, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial, J Clin Oncol, 27, 5431, 10.1200/JCO.2008.20.1228 · DOI · Paper page
  59. Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022 · DOI · Paper page
  60. Ang, 2013, Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study, Clin Cancer Res, 44, 1
  61. Ceccaldi, 2015, A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance, Cancer Res, 75, 1, 10.1158/0008-5472.CAN-14-2593 · DOI
  62. Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791 · DOI · Paper page

Cited by

See all 239

Metadata

Authors
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S.
Venue
European Urology
Publisher
Elsevier BV
Published
2017-03
Volume
71
Issue
3
Pages
417-425
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2510940971
Cited by
239
References
11
FWCI
21.72
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNA Repair in Prostate Cancer: Biology and Clinical Implications. https://app.cochat.ai/papers/10.1016/j.eururo.2016.08.037
The paper
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P. S., Olmos, D., Pritchard, C. C., Rubin, M. A., & de Bono, J. S. (2017). DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology. https://doi.org/10.1016/j.eururo.2016.08.037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.